Ranbaxy Laboratories, India’s largest pharmaceutical company, is celebrating its 20th anniversary in Ukraine. Establishing its operation in the Ukraine market in 1993, Ranbaxy is today the number 1 player in the target market segment with key brands such as Cifran (Ciprofloxacin), Zanocin (Ofloxacin) and Ketanov (Ketorolac) and a market share of 10.3% (Morion, MAT Q3, 2013).
Over the past two decades, the company has established a robust distribution network in Ukraine and is today catering to 25 regions. The company markets branded generic and over-the-counter (OTC) products and is well known for its innovative marketing capabilities with a number of brands in leadership position.
Besides, the therapeutic segments cover anti-infectives, gastrointestinal, cardiovascular, non-steroidal anti-inflammatory drugs (NSAID), urology, OTC and Anti-retrovirals (ARVs). Some of the leading brands in Ukraine include Ketanov, Pylobact NEO, Candesar range, Cifran, Synerpen and Faringosept. The company has in the past, bagged the prestigious Panacea Award for Ketanov, Cifran and Faringosept.
